Graduate Program in Mathematical, Computational and Systems Biology, University of California, Irvine, Irvine, United States; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States
Abdon Iniguez
Graduate Program in Mathematical, Computational and Systems Biology, University of California, Irvine, Irvine, United States; Center for Complex Biological Systems, University of California, Irvine, Irvine, United States
Nilamani Jena
Department of Medicine, University of California, Irvine, Irvine, United States
Prasanthi Tata
Department of Medicine, University of California, Irvine, Irvine, United States
Zhong-Ying Liu
Department of Medicine, University of California, Irvine, Irvine, United States
Center for Complex Biological Systems, University of California, Irvine, Irvine, United States; Department of Developmental and Cell Biology, University of California, Irvine, Irvine, United States; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States; Department of Biomedical Engineering, University of California, Irvine, Irvine, United States
Center for Complex Biological Systems, University of California, Irvine, Irvine, United States; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States; Department of Biomedical Engineering, University of California, Irvine, Irvine, United States; Department of Mathematics, University of California, Irvine, Irvine, United States
Center for Complex Biological Systems, University of California, Irvine, Irvine, United States; Department of Medicine, University of California, Irvine, Irvine, United States; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, United States
Chronic myeloid leukemia (CML) is a blood cancer characterized by dysregulated production of maturing myeloid cells driven by the product of the Philadelphia chromosome, the BCR-ABL1 tyrosine kinase. Tyrosine kinase inhibitors (TKIs) have proved effective in treating CML, but there is still a cohort of patients who do not respond to TKI therapy even in the absence of mutations in the BCR-ABL1 kinase domain that mediate drug resistance. To discover novel strategies to improve TKI therapy in CML, we developed a nonlinear mathematical model of CML hematopoiesis that incorporates feedback control and lineage branching. Cell–cell interactions were constrained using an automated model selection method together with previous observations and new in vivo data from a chimeric BCR-ABL1 transgenic mouse model of CML. The resulting quantitative model captures the dynamics of normal and CML cells at various stages of the disease and exhibits variable responses to TKI treatment, consistent with those of CML patients. The model predicts that an increase in the proportion of CML stem cells in the bone marrow would decrease the tendency of the disease to respond to TKI therapy, in concordance with clinical data and confirmed experimentally in mice. The model further suggests that, under our assumed similarities between normal and leukemic cells, a key predictor of refractory response to TKI treatment is an increased maximum probability of self-renewal of normal hematopoietic stem cells. We use these insights to develop a clinical prognostic criterion to predict the efficacy of TKI treatment and design strategies to improve treatment response. The model predicts that stimulating the differentiation of leukemic stem cells while applying TKI therapy can significantly improve treatment outcomes.
